(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 33.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.13%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Codexis's revenue in 2025 is $49,815,000.On average, 4 Wall Street analysts forecast CDXS's revenue for 2025 to be $5,446,220,373, with the lowest CDXS revenue forecast at $5,401,484,155, and the highest CDXS revenue forecast at $5,509,182,459. On average, 4 Wall Street analysts forecast CDXS's revenue for 2026 to be $6,624,274,126, with the lowest CDXS revenue forecast at $6,180,225,735, and the highest CDXS revenue forecast at $7,782,445,115.
In 2027, CDXS is forecast to generate $11,410,221,053 in revenue, with the lowest revenue forecast at $11,410,221,053 and the highest revenue forecast at $11,410,221,053.